Evaluate Vantage Homepage
Merck boosts Pfizer’s Covid antiviral advantage
Efficacy of Merck/Ridgeback’s molnupiravir shows an alarming fall-off, just as a US regulatory panel review beckons.
Covid-19 scrambles big medtech’s spending
Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.
Gilead pause adds to Merck’s HIV doubts
Could Gilead soon be looking for a new partner for its long-acting project lenacapavir?
Medtech
Covid-19 scrambles big medtech’s spending
Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.
Company Events
Go or no go? Argenx's December showdown
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
The quest for efficacy in pancreatic cancer
Late-stage therapies from Fibrogen, Tyme and Novartis need to avoid the same pitfalls as Erytech and Rafael.
Interviews
Investors back Quell’s Treg approach
Quell should soon join Sangamo in the clinic, while a number of engineered Treg players are at the preclinical stage.
Global Blood takes on gene therapy
Proof-of-concept data at Ash should give clues about whether GBT021601 could be an oral functional cure for sickle cell disease.
Vertex goes small with Mammoth deal
Vertex strikes yet another gene editing deal, this time with the “ultra-small” Crispr specialist Mammoth.